Niraparib + Radiation for Brain Tumor
Trial Summary
Do I need to stop my current medications to join the trial?
The protocol does not specify if you need to stop all current medications. However, if you are using coumarin-derived anticoagulants, you must discontinue them before surgery. Also, if you've had chemotherapy, a 21-day washout period is required before starting the trial.
Will I have to stop taking my current medications?
The trial requires a washout period (time without taking certain medications) of at least 21 days between the last chemotherapy and the start of the study. If you are taking coumarin-derived anticoagulants, you must stop them before surgery, but other anticoagulants like heparin are allowed.
What data supports the idea that Niraparib + Radiation for Brain Tumor is an effective treatment?
The available research shows that Niraparib, when combined with radiation, can make cancer cells more sensitive to the treatment. For example, studies have shown that Niraparib helps enhance the effects of radiation on lung, breast, and prostate cancer cells, making them more likely to be destroyed. Additionally, a case report highlighted the successful use of Niraparib in treating brain metastases from endometrial cancer, where the patient remained free of disease progression for 6 months. This suggests that Niraparib can effectively reach the brain and improve treatment outcomes. However, there is no direct data on its use specifically for brain tumors, so more research is needed to confirm its effectiveness for this condition.12345
What data supports the effectiveness of the drug Niraparib combined with radiation therapy for treating brain tumors?
Research shows that Niraparib, a drug that helps prevent cancer cells from repairing themselves, can make cancer cells more sensitive to radiation. This combination has been effective in treating various cancers, including lung, breast, and prostate cancers, and has shown promise in treating brain metastases from endometrial cancer.12345
What safety data exists for the combination of Niraparib and radiation therapy?
The safety data for Niraparib primarily comes from its use in ovarian cancer trials, where it has shown significant adverse events, including hematologic issues like thrombocytopenia, anemia, and neutropenia, as well as gastrointestinal events. These adverse events led to dose interruptions and reductions in a significant number of patients. While there is research on Niraparib's radiosensitization effects in various cancer cell lines, including head and neck, lung, breast, prostate, and melanoma, specific safety data for its combination with radiation therapy in brain tumors is not directly available from the provided studies. The existing studies suggest that Niraparib can enhance the effects of radiation on cancer cells, but the impact on healthy tissues and overall safety in a clinical setting requires further investigation.23467
Is the combination of Niraparib and radiation therapy safe for humans?
Niraparib has been studied in combination with radiation therapy for various cancers, and while it shows promise in enhancing the effects of radiation on cancer cells, it can cause side effects. In trials for ovarian cancer, nearly all patients experienced some side effects, with serious ones like low blood cell counts being common. The combination with radiation may increase sensitivity in cancer cells, but healthy cells can also be affected, so careful monitoring is needed.23467
Is the drug Niraparib a promising treatment for brain tumors?
How is the drug Niraparib unique in treating brain tumors?
What is the purpose of this trial?
This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss. The trial will be composed of a Phase 0 component (subdivided into Arm A and B) and a therapeutic expansion phase. Patients with tumors demonstrating a positive PK Response (in Arm A) or a positive PD Response (in Arm B) of the Phase 0 component of the study will graduate to a therapeutic expansion phase that combines therapeutic dosing of niraparib plus standard-of-care fractionated radiotherapy (in Arm A) or niraparib monotherapy (in Arm B) until progression of disease.
Research Team
Nader Sanai, MD
Principal Investigator
Chief Scientific Officer/Director of the Ivy Brain Tumor Center
Eligibility Criteria
Adults over 18 with newly-diagnosed glioblastoma or recurrent glioma with specific genetic mutations can join. They must have recovered from any previous chemotherapy, have normal blood pressure, adequate organ function, and not be pregnant or breastfeeding. Participants need to agree to use effective contraception and adhere to lifestyle considerations for the study duration.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 0
Participants receive niraparib for 4 days prior to surgical resection
Therapeutic Expansion
Participants receive niraparib plus standard-of-care fractionated radiotherapy or niraparib monotherapy until disease progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Niraparib
- Radiation therapy
Niraparib is already approved in European Union, United States, Canada for the following indications:
- Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
- Maintenance treatment of adults with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy
- Maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy
- Treatment of adults with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status
- Maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nader Sanai
Lead Sponsor
University of California, San Francisco
Collaborator
GlaxoSmithKline
Industry Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Barrow Neurological Institute
Collaborator
Ivy Brain Tumor Center
Collaborator